Daily salbutamol in young patients with SMA type II
M Pane, S Staccioli, S Messina, A D'Amico… - Neuromuscular …, 2008 - Elsevier
The aim of this open pilot study was to establish the profile of tolerability and clinical
response of salbutamol (albuterol) in a cohort of young children affected by type II spinal
muscular atrophy (SMA). Twenty-three children between 30 months and 6 years of age were
treated with salbutamol (2mg three times a day) for 1 year. All children were longitudinally
assessed using the Hammersmith motor functional scale 6 months before treatment started
(T0), at baseline (T1) and 6 and 12 months later. There was no significant change in function …
response of salbutamol (albuterol) in a cohort of young children affected by type II spinal
muscular atrophy (SMA). Twenty-three children between 30 months and 6 years of age were
treated with salbutamol (2mg three times a day) for 1 year. All children were longitudinally
assessed using the Hammersmith motor functional scale 6 months before treatment started
(T0), at baseline (T1) and 6 and 12 months later. There was no significant change in function …